Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

(2017) Kevin Fitzgerald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients

(2017) John Munkhaugen et al.   European Journal of Preventive Cardiology

Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey

(2016) Ž. Reiner et al.   ATHEROSCLEROSIS

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia

(2015) Eliano Pio Navarese et al.   ANNALS OF INTERNAL MEDICINE

A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins

(2015) Joseph L. Goldstein et al.   CELL

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-ITCLINICAL PERSPECTIVES

(2015) Erin A. Bohula et al.   CIRCULATION

Prognostic value of PCSK9 levels in patients with acute coronary syndromes

(2015) Baris Gencer et al.   EUROPEAN HEART JOURNAL

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis

(2015) Michael J. Lipinski et al.   EUROPEAN HEART JOURNAL

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

(2014) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

(2014) S. Matthijs Boekholdt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Targeting PCSK9 for Hypercholesterolemia

(2013) Giuseppe Danilo Norata et al.   Annual Review of Pharmacology and Toxicology

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin‐Treated Subjects From 3 Data Sources: A Retrospective Analysis

(2013) Peter H. Jones et al.   Journal of the American Heart Association

Cardiovascular disease risk reduction by raising HDL cholesterol - current therapies and future opportunities

(2012) K Mahdy Ali et al.   BRITISH JOURNAL OF PHARMACOLOGY

Combating the Epidemic of Heart Disease

(2012) Daniel Levy   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality

(2012) Ian Graham et al.   Current Cardiology Reports

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A systematic review and meta-analysis on the therapeutic equivalence of statins

(2009) T.-C. Weng et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS